Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$4.25 USD
-0.11 (-2.52%)
Updated Oct 13, 2025 04:00 PM ET
After-Market: $4.24 -0.01 (-0.24%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Larimar Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Drugs industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
LRMR 4.25 -0.11(-2.52%)
Will LRMR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for LRMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LRMR
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
LRMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Other News for LRMR
Is LRMR signaling selling opportunity? Fell Below 20 Day Moving Average shows up after slipping 4.18%
LRMR forms NR7 on October 9
Calm After Storm appears for LRMR after 2.12% move
Calm After Storm appears for LRMR after 1.87% move
Truist Financial Sticks to Its Buy Rating for Larimar Therapeutics (LRMR)